"FDA Approves Selinexor in Relapsed/Refractory Multiple Myeloma" - Gina Columbus
The FDA has granted an accelerated approval to Selinexor for use in combination with dexamethasone for the treatment of adult patients with relapsed/refractory multiple myeloma. “The 25.3 percent response rate seen in the subgroup of 83 patients in the pivotal phase IIb STORM study that served as the basis for Xpovio's accelerated approval is clinically meaningful and a validated surrogate marker for clinical benefit in our patients with advanced refractory disease," said Sundar Jagannath, MD, director of the myeloma program at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai.
— Sundar Jagannath, MD, Professor, Medicine, Hematology, Medical Oncology, Director, Myeloma Program, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai
Unprecedented Therapy Found Effective for Blood Cancer Patients With No Treatment Options
Aug 22, 2019 View All Press Releases